Granadillo M, Torrens I, Guerra M, Batte A, Soria Y, Mendoza O, Blanco A, Musacchio A, Lugo VM

Idioma: Ingles.
Referencias bibliográficas: 6
Paginas: 194-197
Archivo PDF: 199.38 Kb.

RESUMEN

Facilitating the delivery of exogenous antigens to antigen-presenting cells, ensuing processing and presentation via the major histocompatibility complex class I and induction of an effective immune response are fundamental for an effective therapeutic cancer vaccine. In this regard, we propose the use of cell-penetrating peptides fused to a tumor antigen. To demonstrate this concept we designed a fusion protein comprising a novel cell-penetrating and immunostimulatory peptide corresponding to residues 32 to 51 of the Limulus anti-lipopolysaccharide factor protein (LALF_32-51) linked to human papillomavirus 16 E7 antigen (LALF_32-51-E7). In this work, we demonstrated that the immunization with LALF_32-51-E7 using the TC-1 mouse model induces a potent and long-lasting anti-tumor response supported on an effective E7-specific CD8+ T-cell response. The finding that therapeutic immunization with LALF_32-51 or E7 alone, or an admixture of LALF_32-51 and E7, does not induce significant tumor reduction indicates that covalent linkage between LALF_32-51 and E7 is required for the anti-tumor effect. These results support the use of this novel cell-penetrating peptide as an efficient means for delivering therapeutic targets into cellular compartments with the induction of a cytotoxic CD8+ T lymphocyte immune response. This approach is promissory for the treatment of tumors associated with the human papillomavirus 16, which is responsible for the 50% of cervical cancer cases worldwide and other malignancies. Furthermore, protein-based vaccines can circumvent the major histocompatibility complex specificity limitation associated with peptide vaccines providing a greater extent in their application.

REFERENCIAS (EN ESTE ARTÍCULO)

1. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009;384(2): 260-5.

2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342-50.

3. Su JH, Wu A, Scotney E, Ma B, Monie A, Hung CF, et al. Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs. 2010;24(2):109-29.

4. Granadillo M, Vallespi MG, Batte A, Mendoza O, Soria Y, Lugo VM, et al. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice. Vaccine. 2011;29(5):920-30.

5. Yero D, Pajon R, Niebla O, Sardinas G, Vivar I, Perera Y, et al. Bicistronic expression plasmid for the rapid production of recombinant fused proteins in Escherichia coli. Biotechnol Appl Biochem. 2006;44(Pt 1):27-34.

6. Lin KY, Guarnieri FG, Staveley-O’Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56(1):21-6.